Science, research and developmentEuropean Commission LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH Applications of knowledge and technologies in

Science, research and development European Commission

LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH

Applications of knowledge and technologies

in the field of genomics and biotechnology

for healthAlfredo Aguilar

Head of Unit Biotechnology and Applied Genomics

Directorate Life Sciences EDirectorate General Research

European Commission

NCPs FP6, Theme 1Brussels, 23 October 2002



Strategic objective:

To foster the competitiveness of Europe’s biotechnology industry by exploiting the wealth of biological data produced by genomics and advances in biotechnology.

Applications of knowledge and technologiesin the field of genomics and biotechnology for

health



• Rational and accelerated development of new, safer and more effective drugs including pharmacogenomics approaches


healthTechnology Platforms will focus their research

activities on:

• Development of new diagnostics• Development of new in vitro tests to replace animal

experimentation• Testing of new preventive and therapeutic tools such as somatic gene and cell tehrapies (in particular stem cell therapies) and immunotherapies• Innovative research in post-genomics (novel products from genomics and biotechnology)

Technology platforms are particularly suited for SME.



How the objective is to be achieved ?


health

“TRANSLATIONAL APPROACH”

Application stage to enablereal, consistent and coordinated

progress at European level in medicine, competitiveness

and in the quality of life

Bringing basic

knowledge



Is basic research ? Applied research ?Successful projects must develop

an Integrated Multidisciplinary Research


health

Integration

• Biology and Technology• Technology producers and Technology users• Stakeholders (Extended Audiences)• SME in the projects (15% of budget for SME!)• Innovation and exploitation






health

Multidisciplinary

• Cutting across S&T disciplines• Approaching lateral issues• Interphase between disciplines






health

ResearchProjects may include basic, applied research,demonstration activities provided that...

• is transnational research (clear deliverables; basic knowledge to application stage)• address major societal needs• increases EU competitiveness



How to combine improvement of Europe’s biotechnology industry and precompetitive projects ?


health

TECHNOLOGICAL PLATFORMS

IntegratedMultidisciplinaryResearch

EU project

- Health care progress- Increased quality of life- Cost reduction- Precise diagnostics- Individualised treatments- New drugs and therapies- Novel products from genomicsand biotechnology

Socio-economic deliverables, competitive projects

• Industry• SME• Academics• Stakeholders

Civil society

Through the development of technological platforms



TOTAL NoE IPFundamental Genomics 523 30 10 20Applied Genomics and

Biotechnology401 40* 11 20

Medical Application Oriented Genomics

Approaches702 33* 13 18

Combating Cancer 302 14 5 9Poverty related Diseases 69 10 2 8

TOTAL 1997 127* 41 75

Total EoI Received

Selected Topics

Priority 1Research topics of European strategic

importancefor possible implementation via a new

instrument

* some of which addressed by NoE and/or IP



From EoI analysis to the work probramme for the first FP6 call

• Preparation of the work programme for the first call of FP6 is based on EoI analysis but will require further focusing due to budgetary limitations and…

• Strategic input from inter-service consultations, Expert Advisory Groups and the Programme Committee

• A conference marking the launch of the FP6 will take place in Brussels on November 11-13/2002

• Publication first calls for proposals in the Official Journal expected on 17 December 2002 (deadline 17 March 2003)



From the Expressions of Interest to the Draft Workprogramme:


health

Relevant topics stemming from the EoI

- Blood substitutes- Antiviral therapeutics- New drugs from novel sources- Genome based individualised medicines- Novel therapies for neurodegenerative disorders in CNS and PNS- Genome-based anti-psychotic therapies- Signal transduction pathways as targets for disease detection and treatment- Development of medicines in pediatrics- Computer assisted modeling for drug discovery and clinical trials

Rational and accelerated development of new, safer and more effective drugs including pharmacogenomics approaches





health


- In vivo molecular imaging- Reference systems for genetic testing- Non-invasive (including prenatal) diagnostics; development of markers for ante- and neo-natal screening

Development of new diagnostics





health


In vitro alternatives to animal and human toxicology testing:

- Development of innovative methods, technology, strategies- Application of in vitro methods

Development of new in vitro tests to replace animal experimentation





health


- Connective tissue disorders: bone diseases, osteoarthritis- Organ repair: hepatic, hemopoietic, neural tissue- Biobanks- Translation of stem cell biology into new cell-based therapies and novel targets for drug development and other therapeutic products- Stem cell development for the regeneration of hemopoietic, hepatic, cardiac, neural, mesenchymal and connective tissues- Sem cell development, technical standardisation, benchmarking, development of reference materials- Stem cell therapies: standardisation, characterisation and protocol validation

Development and testing of new preventive and therapeutic tools such as somatic, gene and cell therapies (in particular stem cell

therapies) and immunotherapies (i)





health


- New improved vaccine technologies- Immunotherapy for auto-immune diseases- Plant based vaccines - plant biotechnology for global health- Viral and non-viral delivery systems- Cell targeting- Standardisation and characterisation in gene therapy- Gene therapy for genetic diseases- Dendritic cells, chemokines, cytokines- Allergy, autoimmunity, inflammatory disease- Prevention and treatment of disease through modulation of the immune system

Development and testing of new preventive and therapeutic tools such as somatic, gene and cell therapies (in particular stem cell

therapies) and immunotherapies (ii)





health

Relevant topics stemming from the EoI- Functional analysis of human genome and its application to diagnosis and therapy of diseases, including mitochondrial disorders- Adverse reactions to drugs, in particular those of immunological origin- Quality and safety control of new tools (gene vectors, stem cells) for clinical use- Optimisation, standardisation and quality assessment and assurance of postgenomic technology- Post-genomic approaches for allergy and autoimmune diseases: * for complex multifactorial diseases * for the development of new tools for the rapid diagnosis of pathogenic infection and new targets for anti-microbial agents - New strategies for large scale analysis and high throughput screening in the postgenomic- RNA tools for gene function analysis

Innovative research in post-genomics



Networks of Excellence: Objectives

To structure the EU research potential

by integrating research capacities• Joint research activities• Integrating activities• Spreading of excellence• Common management

Management Group

Eu

rop

ean

Com

mis

sion

Research team leader

Management Group

• Joint research activities• Integrating activities• Spreading of excellence (training)• Common management

To structure the EU research potential by integrating existing research capacities

Governing Council Funding Bodies Representatives

Partner Organisation Representative

Scientific Council



Integrated projects: Objectives

Training

Ethical aspects, science-society dialogueEthical aspects, science-society dialogue

Technology transfer, exploitationTechnology transfer, exploitation

strong managementstructure

ImplementationPlan

RTD 4

RTD 1

RTD 2

RTD 3

RTD 5

Demonstration

ManagementManagement

addressing major societal needs increasing EU competitiveness

predefined S/Tresults and

clear deliverables

To integrate the critical mass of activities/resources needed for :



Main challenges:

• To guarantee a higher success rate than in FP5

• To attract SME (4% industries in the EoI for TP1, 10% for this

area)

• To attract oustanding IP and NoE (FP6 projects are not “big” FP5

projects)


health



Ongoing and coming trends...• 17 December 2002, First Call for Proposals, Framework

Programme 6To keep you informed with the latest news…

www.cordis.lu/fp6/eoi-instruments

… and with the new instruments, rules for participation,…

http://europa.eu.int/comm/research/nfp/networks-ip.html

Help and information :

for Priority “Life Sciences, Genomics and Biotechnology for Health”: [email protected]

Opportunities for Life Sciences, Genomics and Biotechnology for Healthin Framework Programme 6 (2002-2006)

Documents

Science, research and developmentEuropean Commission LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH Applications of knowledge and technologies in